You are Here:
23 and Me and GlaxoSmithKline

Author (Read 2197 times)

0 Members and 1 Guest are viewing this topic.

23 and Me and GlaxoSmithKline
« on: Aug 10, 2018, 10:55:32 am »


  • Global Moderator
  • Mega InfoWarrior
  • *****
  • 1665
  • Teach yourself
I sure hope y'all aren't falling for all this ancestry/genetic/hereditary research crap. The search for the Holy Grail continues. Are you of approved blood? Ready for your DNA to be used as these companies please? Just look at this little bit...

GlaxoSmithKline strikes $300 million deal with 23andMe for genetics-driven drug research

Meg Tirrell | @megtirrell Published 6:23 AM ET Wed, 25 July 2018 Updated 3:15 PM ET Wed, 25 July 2018

British drug giant GlaxoSmithKline is investing $300 million in consumer genetics company 23andMe, forging a four-year collaboration to discover medicines using human genetics as a guide.

The partnership establishes GSK as 23andMe’s exclusive collaborator for drug target discovery, the companies said Wednesday. It comes with an option to extend for a fifth year, and funding and proceeds will be split equally.

The announcement comes as GSK embarks on a new research strategy under new Chief Scientific Officer Hal Barron, a drug industry veteran. The new approach focuses on the immune system, genetics and advanced analytics and technology.

It’s not the first time a pharmaceutical company has turned to genetics to improve its drug development. Amgen acquired Iceland’s deCODE Genetics in 2012 for $415 million to benefit from its unique genetic database, while Regeneron has partnered with Geisinger Health and the UK Biobank to do the same.

23andMe is a different kind of partner. It’s a direct-to-consumer genetic testing company that charges $199 for certain health and ancestry data ($99 just for ancestry). The company has more than 5 million customers, 80 percent of whom have consented to participating in research.

It doesn’t have the traditional health records that a system like Geisinger does, but conducts surveys of its users, and says, on average, one person in its database contributes to 200 different research studies.

The company has been focused on drug development of its own, hiring Genentech veteran Richard Scheller in 2015 as chief scientific officer and head of therapeutics.

Together, the companies aim to use 23andMe’s genetic database to improve selection of drug targets, finding medicines that are more likely to work and carry a lower safety risk. The collaboration is also designed to speed identification and recruitment of patients for clinical trials.

I know where my ancestors came from in Europe to America in the late 1800s and early 1900s. If I didn't, what would it really even matter? We're Americans and my ancestors left behind Europe for a reason. I'm not white. I'm not Italian. I'm not Irish. I'm not German. I'm not Scottish. I'm not French. I'm AMERICAN dammit!

Last Edit by Humphrey
"Castles made of sand, slips into the sea, eventually." - Jimi Hendrix


Powered by EzPortal